{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:11:01Z","timestamp":1744179061705},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T00:00:00Z","timestamp":1513555200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Netw Model Anal Health Inform Bioinforma"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s13721-017-0163-8","type":"journal-article","created":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T10:59:10Z","timestamp":1513594750000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Trifluorophenyl-based inhibitors of dipeptidyl peptidase-IV as antidiabetic agents: 3D-QSAR COMFA, CoMSIA methodologies"],"prefix":"10.1007","volume":"7","author":[{"given":"M. C.","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,18]]},"reference":[{"key":"163_CR1","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1556\/OH.2010.28910","volume":"151","author":"T Abel","year":"2010","unstructured":"Abel T, Feher J (2010) A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (Sitagliptin). Orvsi Hetil 151:1012\u20131016","journal-title":"Orvsi Hetil"},{"key":"163_CR2","doi-asserted-by":"crossref","first-page":"6525","DOI":"10.1016\/j.bmcl.2008.10.076","volume":"18","author":"JH Ahn","year":"2008","unstructured":"Ahn JH, Park WS, Jun MA, Shin MS, Kang SK, Kim KY, Rhee SD, Bae MA, Kim KR, Kim SG, Kim SY, Sohn SK, Kang NS, Lee JO, Lee DH, Cheon HG, Kim SS (2008) Synthesis and biological evaluation of homopiperazine derivatives with beta-aminoacyl group as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 18:6525\u20136529","journal-title":"Bioorg Med Chem Lett"},{"key":"163_CR3","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1021\/jm050261p","volume":"48","author":"DJ Augeri","year":"2005","unstructured":"Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, Han SP, Abboa-Offei B, Cap M, Xin L, Tao L, Tozzo E, Welzel GE, Egan DM, Marcinkeviciene J, Chang SY, Biller SA, Kirby MS, Parker RA, Hamann LG (2005) Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:5025\u20135037","journal-title":"J Med Chem"},{"key":"163_CR4","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1517\/14656566.8.15.2593","volume":"8","author":"A Barnett","year":"2007","unstructured":"Barnett A (2007) Exenatide. Exp Opin Pharmacother 8:2593\u20132608","journal-title":"Exp Opin Pharmacother"},{"key":"163_CR5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/BF00124364","volume":"7","author":"BL Bush","year":"1993","unstructured":"Bush BL, Nachbar RB Jr (1993) Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J Comput Aided Mol Des 7:587\u2013619","journal-title":"J Comput Aided Mol Des"},{"issue":"18","key":"163_CR6","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1021\/ja00226a005","volume":"110","author":"RD Cramer","year":"1988","unstructured":"Cramer RD, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110(18):5959\u20135967","journal-title":"J Am Chem Soc"},{"key":"163_CR7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1358\/dot.1999.35.3.533845","volume":"35","author":"CF Deacon","year":"1999","unstructured":"Deacon CF, Holst JJ, Carr RD (1999) Glucagon-like peptide-1: a basis for new approaches to the management of diabetes. Drugs Today (Barc) 35:159\u2013170","journal-title":"Drugs Today (Barc)"},{"key":"163_CR8","doi-asserted-by":"crossref","first-page":"43S","DOI":"10.1592\/phco.29.pt2.43S","volume":"29","author":"SR Drab","year":"2009","unstructured":"Drab SR (2009) Clinical studies of Liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus. Pharmacotherapy 29:43S\u201354S","journal-title":"Pharmacotherapy"},{"issue":"11","key":"163_CR10","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1210\/en.2002-220405","volume":"143","author":"L Farilla","year":"2002","unstructured":"Farilla L (2002) Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143(11):4397\u20134408","journal-title":"Endocrinology"},{"key":"163_CR11","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1021\/jm070104l","volume":"50","author":"J Feng","year":"2007","unstructured":"Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, Navre M, Shi L, Skene RJ, Asakawa T, Takeuchi K, Xu R, Webb DR, Gwaltney SL 2nd (2007) Discovery of Alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 50:2297\u20132300","journal-title":"J Med Chem"},{"key":"163_CR12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF03366604","volume":"152","author":"B Gallwitz","year":"2010","unstructured":"Gallwitz B (2010) Diabetes therapy novel drugs to come (DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors). MMW Fortschr Med 152:43\u201344","journal-title":"MMW Fortschr Med"},{"issue":"14","key":"163_CR13","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1016\/j.bmcl.2007.04.106","volume":"17","author":"Y-D Gao","year":"2007","unstructured":"Gao Y-D, Feng D, Sheridan RP et al (2007) Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors. Bioorg Med Chem Lett 17(14):3877\u20133879","journal-title":"Bioorg Med Chem Lett"},{"key":"163_CR14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/0091270006295061","volume":"47","author":"YL He","year":"2007","unstructured":"He YL, Horowitz A, Watson CE, Foley JE, Sallas W, Ligueros-Saylan M (2007) Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes. J Clin Pharmacol 47:127\u2013131","journal-title":"J Clin Pharmacol"},{"key":"163_CR15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/sj.clpt.6100167","volume":"81","author":"GA Herman","year":"2007","unstructured":"Herman GA, Stein PP, Thornberry NA, Wagner JA (2007) Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on Sitagliptin. Clin Pharmacol Ther 81:761\u2013767","journal-title":"Clin Pharmacol Ther"},{"key":"163_CR16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3810\/pgm.2010.05.2144","volume":"122","author":"PA Hollander","year":"2010","unstructured":"Hollander PA, Kushner P (2010) Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med 122:71\u201380","journal-title":"Postgrad Med"},{"issue":"3","key":"163_CR17","first-page":"533","volume":"2","author":"S Janardhan","year":"2011","unstructured":"Janardhan S, Padmanabha Reddy Y (2011) Molecular modeling studies of \u03b2-aminoacyl containing homopiperazine derivatives as DPP 4 inhibitors. Int J Drug Des Discov 2(3):533\u2013547","journal-title":"Int J Drug Des Discov"},{"issue":"7","key":"163_CR18","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00894-009-0637-4","volume":"16","author":"Y-K Jiang","year":"2010","unstructured":"Jiang Y-K (2010) Molecular docking and 3D-QSAR studies on \u03b2-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors. J Mol Model 16(7):1239\u20131249","journal-title":"J Mol Model"},{"key":"163_CR19","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.ejmech.2007.11.029","volume":"43","author":"MA Jun","year":"2008","unstructured":"Jun MA, Park WS, Kang SK, Kim KY, Kim KR, Rhee SD, Bae MA, Kang NS, Sohn SK, Kim SG, Lee JO, Lee DH, Cheon HG, Kim SS, Ahn JH (2008) Synthesis and biological evaluation of pyrazoline analogues with beta-amino acyl group as dipeptidyl peptidase IV inhibitors. Eur J Med Chem 43:1889\u20131902","journal-title":"Eur J Med Chem"},{"key":"163_CR20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1021\/jm0493156","volume":"48","author":"D Kim","year":"2005","unstructured":"Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE (2005) (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:141\u2013151","journal-title":"J Med Chem"},{"key":"163_CR21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1021\/jm070330v","volume":"51","author":"D Kim","year":"2008","unstructured":"Kim D, Kowalchick JE, Brockunier LL, Parmee ER, Eiermann GJ, Fisher MH, He H, Leiting B, Lyons K, Scapin G, Patel SB, Petrov A, Pryor KD, Roy RS, Wu JK, Zhang X, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE (2008) Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing substituted triazolopiperazines. J Med Chem 51:589\u2013602","journal-title":"J Med Chem"},{"key":"163_CR22","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1021\/jm00050a010","volume":"37","author":"G Klebe","year":"1994","unstructured":"Klebe G, Abraham U, Mietzner T (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37:4130\u20134146","journal-title":"J Med Chem"},{"key":"163_CR23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jmgm.2011.10.001","volume":"32","author":"V Kovalishyn","year":"2012","unstructured":"Kovalishyn V, Tanchuk V, Charochkina L et al (2012) Predictive QSAR modeling of phosphodiesterase 4 inhibitors. J Mol Graph Model 32:32\u201338","journal-title":"J Mol Graph Model"},{"key":"163_CR24","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/clpt.2010.184","volume":"88","author":"EM Migoya","year":"2010","unstructured":"Migoya EM, Bergeron R, Miller JL, Snyder RN, Tanen M, Hilliard D, Weiss B, Larson P, Gutierrez M, Jiang G, Liu F, Pryor KA, Yao J, Zhu L, Holst JJ, Deacon C, Herman G, Thornberry N, Amatruda J, Williams-Herman D, Wagner JA, SinhaRoy R (2010) Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 88:801\u2013808","journal-title":"Clin Pharmacol Ther"},{"key":"163_CR25","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1016\/j.bmcl.2009.06.036","volume":"19","author":"S Nordhoff","year":"2009","unstructured":"Nordhoff S, L\u00f3pez-Canet M, Hoffmann-Enger B, Bulat S, Cerezo-G\u00e1lvez S, Hill O, Rosenbaum C, Rummey C, Thiemann M, Matassa VG, Edwards PJ, Feurer A (2009) From lead to preclinical candidate optimization of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV. Bioorg Med Chem Lett 19:4818\u20134823","journal-title":"Bioorg Med Chem Lett"},{"key":"163_CR26","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jfluchem.2009.08.001","volume":"130","author":"WS Park","year":"2009","unstructured":"Park WS, Jun MA, Shin MS, Kwon SW, Kang SK, Kim KY, Dal Rhee S, Bae MA, Narsaiah B, Lee DH, Cheon HG, Ahn JH, Kim SS (2009) Synthesis and biological evaluation of triazepane derivatives as DPP-IV inhibitors. J Fluor Chem 130:1001\u20131010","journal-title":"J Fluor Chem"},{"key":"163_CR27","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.bmcl.2004.01.019","volume":"14","author":"JU Peters","year":"2004","unstructured":"Peters JU, Weber S, Kritter S, Weiss P, Wallier A, Boehringer M, Hennig M, Kuhn B, Loeffler BM (2004) Aminomethylpyrimidines as novel DPP-IV inhibitors: a 10(5)-fold activity increase by optimization of aromatic substituents. Bioorg Med Chem Lett 14:1491\u20131493","journal-title":"Bioorg Med Chem Lett"},{"issue":"10","key":"163_CR28","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00894-007-0227-2","volume":"13","author":"RRS Pissurlenkar","year":"2007","unstructured":"Pissurlenkar RRS, Shaikh MS, Coutinho EC (2007) 3D-QSAR studies of dipeptidyl peptidase IV inhibitors using a docking based alignment. J Mol Model 13(10):1047\u20131071","journal-title":"J Mol Model"},{"key":"163_CR30","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1021\/jm025522z","volume":"45","author":"EB Villhauer","year":"2002","unstructured":"Villhauer EB, Brinkman JA, Naderi GB, Dunning BE, Mangold BL, Mone MD, Russell ME, Weldon SC, Hughes TE (2002) 1-[2-[(5-Cyanopyridine-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 45:2362\u20132365","journal-title":"J Med Chem"},{"issue":"3","key":"163_CR31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1021\/ci00063a006","volume":"29","author":"VN Viswanadhan","year":"1989","unstructured":"Viswanadhan VN, Ghose AK, Revankar RG, Robins RK (1989) Atomic physicochemical parameters for three dimensional structure directed quantitative structure\u2013activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J Chem Inf Comput Sci 29(3):163\u2013172","journal-title":"J Chem Inf Comput Sci"}],"container-title":["Network Modeling Analysis in Health Informatics and Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13721-017-0163-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13721-017-0163-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13721-017-0163-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T07:20:04Z","timestamp":1544426404000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13721-017-0163-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,18]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["163"],"URL":"https:\/\/doi.org\/10.1007\/s13721-017-0163-8","relation":{},"ISSN":["2192-6662","2192-6670"],"issn-type":[{"value":"2192-6662","type":"print"},{"value":"2192-6670","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,18]]},"article-number":"1"}}